statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer...

Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum

This indicator may be signaling DCPH's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Deciphera Pharmaceuticals (DCPH, $15.76) entered Uptrend as Momentum indicator ascends above 0 level on Apr 01, 2024

This price move could indicate a change in the trend, and may be a buy signal for investors...

Deciphera Pharmaceuticals (DCPH, $15.71) price moved above its 50-day Moving Average on March 28, 2024

Deciphera Pharmaceuticals (NASDAQ:DCPH  Free Report) had its target price increased by JPMorgan Chase & Co. from $14.00 to $16.00 in a report released on Wednesday morning, Benzinga reports...

JPMorgan Chase & Co. Raises Deciphera Pharmaceuticals (NASDAQ:DCPH) Price Target to $16.00

This price move could indicate a change in the trend, and may be a sell signal for investors...

Deciphera Pharmaceuticals (DCPH, $15.23) price exceeded its 50-day Moving Average on March 22, 2024

Deciphera Pharmaceuticals (DCPH, $15.75) price moved above its 50-day Moving Average on March 20, 2024

Deciphera Pharmaceuticals (DCPH, $14.87) price exceeded its 50-day Moving Average on March 18, 2024

This indicator may be signaling that DCPH's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Deciphera Pharmaceuticals (DCPH, $16.09) entered Downtrend as Momentum indicator drops below 0 level on Mar 12, 2024

This is a Bearish indicator signaling DCPH's price could decline from here. Traders may explore shorting the stock or put options...

Deciphera Pharmaceuticals (DCPH, $16.09) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 12, 2024

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.

Volume	401,815.00
52-Wk High	$17.73
52-Wk Low	$9.90

DCPH Deciphera Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals